TMCnet News
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACRImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR Marseille, France, March 14, 2023 – ImCheck Therapeutics today announced that it will present data from its Phase I/IIa clinical trial EVICTION-2 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023. The EVICTION-2 trial is evaluating the combination of ImCheck’s lead program, ICT01, a ?9d2 T cell-activating monoclonal antibody targeting BTN3A, combined with low dose IL-2, to selectively expand the number of ?9d2 T cells in relapsed/refractory patients with solid tumors. The conference will be held in Orlando, Florida, from April 14 to 19, 2023, and clinical trial abstracts will be posted online on April 14. Details of the poster presentation are: *** About the EVICTION 2 Trial About ICT01 As demonstrated in EVICTION data presented at past AACR, EMSO and SITC conferences, ICT01 selectively activates circulating ?9d2 T cells that leads to migration of ?9d2 T cells out of the circulation and into target tissue (e.g., tumors), while also activating the tumor-resident ?9d2 T cells to directly kill malignant cells, which is accompanied by secretion of two key inflammatory cytokines, IFN? and TNFa, that contribute to the expansion of the anti-tumor immune response. ICT01 has been shown to have anti-tumor activity against a range of cancers in in vitro and in vivo tumor models. About IMCHECK THERAPEUTICS ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by its lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune and infectious diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille University), a worldwide leader in ?9d2 T cells and butyrophilins research, as well as from the experience of an expert management team and from the commitment of leading US and European investors. For further information: https://www.imchecktherapeutics.com/ and @ImCheckThx Press contacts: US and EU France Attachment 
|
